| 2 |
Advice on the effectiveness of Tamiflu / vaccines, and how critical staff can get priority access to these.
How can infrastructure providers obtain preferential supplies? |
Transpower (9 August 2005 letter)
New Zealand Refining Company (15 August 2005 letter)
Network Tasman (email 21 October 2005)
STOS (email 19 December 2005) |
MoH (15 August 2005 email)
(Answer updated: May 2006) |
There are no commercial supplies of vaccine against pandemic influenza virus. As yet, pandemic influenza virus does not exist. Many countries are developing prototype vaccines against one of the avian influenza viruses currently considered to be likely to give rise to pandemic influenza. Vaccines are not likely to be available until some months after the virus mutates into a form that can be easily conveyed between humans - only then will it be possible to establish the genetic form of the virus.
New Zealand has entered a formal arrangement with CSL in Australia, the only vaccine manufacturer in the Southern Hemisphere, for a supply of influenza pandemic vaccine once it is developed. From the onset of an influenza pandemic it may take up to six months for a vaccine to be developed and made in sufficient quantities for all New Zealanders.
Several medicines have specific activity against the influenza virus; one of these drugs - the anti-viral medication, Tamiflu - is considered suitable for use in a pandemic situation in New Zealand. As advised by WHO, the New Zealand Government has stockpiled enough Tamiflu for 21% of the population, to help reduce the impact of a pandemic on New Zealanders.
For normal seasonal influenza, Tamiflu, when used correctly, reduces illness and secondary complications, and reduces the period of infection by 1-2 days. It is anticipated that Tamiflu can play a valuable role both for containment of any pandemic at an early stage, and in reducing hospitalisations if the pandemic spreads. However, Tamiflu has not been tested in a pandemic, so there is no guarantee that it will be effective against a pandemic strain.
MoH advises that the Government's stockpile of Tamiflu will be used to treat infected people, and to contain any spread of infection during the "Cluster Control" phase, rather than be allocated for preventative measures (except for first responders, e.g. health workers). Policy concerning the usage of Tamiflu can only be finalised once the nature of the pandemic virus (its epidemiology) can be identified.
Infrastructure providers should proceed with their business continuity planning on the basis that they will not be receiving any Tamiflu (for preventative purposes) from the Government. Organisations should consider the purchase and use of Tamiflu as part of their BCP arrangements.
Refer to the public position statement on Tamiflu on MoH's website (forthcoming). |